drug · antibody

spevatamig

Phase 2updated 3mo ago

by Phanes Therapeutics Inc🔗 ChEMBL

Phase 2

community read0 votes

Antibody drug with a maximum clinical stage of Unknown, with 1 investigational indication.

all catalysts(0)

nothing on the calendar yet

Trials studying spevatamig

phase2Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)recruitingn=258

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 16m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · antibody

save

spevatamig

Phase 2updated 3mo ago

by Phanes Therapeutics Inc🔗 ChEMBL

Phase 2

community read0 votes

Antibody drug with a maximum clinical stage of Unknown, with 1 investigational indication.

all catalysts(0)

nothing on the calendar yet

Trials studying spevatamig

phase2Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)recruitingn=258

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 16m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

spevatamig

all catalysts(0)

Trials studying spevatamig

News(0)

Report a data issue

comments(0)

spevatamig

all catalysts(0)

Trials studying spevatamig

News(0)

Report a data issue

comments(0)